AstraZeneca PLC (FRA:ZEG)
Germany · Delayed Price · Currency is EUR | Market Cap | 237.59B +6.1% |
| Revenue (ttm) | 53.71B +8.6% |
| Net Income | 9.14B +25.9% |
| EPS | 6.01 +25.8% |
| Shares Out | n/a |
| PE Ratio | 25.55 |
| Forward PE | 15.86 |
| Dividend | 2.76 (1.79%) |
| Ex-Dividend Date | Aug 6, 2026 |
| Volume | 1,076 |
| Open | 153.75 |
| Previous Close | 153.80 |
| Day's Range | 151.60 - 153.75 |
| 52-Week Range | 134.00 - 180.45 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 30, 2026 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Topr... [Read more]
Financial Performance
In 2025, AstraZeneca's revenue was $58.74 billion, an increase of 8.63% compared to the previous year's $54.07 billion. Earnings were $10.23 billion, an increase of 45.34%.
Financial numbers in USD Financial StatementsNews
Amgen announces Phase 3 results of Imdelltra with AstraZeneca’s Imfinzi
Amgen (AMGN) announced an interim Phase 3 results showing that Imdelltra in combination with AstraZeneca’s (AZN) Imfinzi reduced the risk of death by 58% as a first-line maintenance treatment for…
AstraZeneca announces results from CLARITY-Gastric01 Phase III trial
Positive results from the CLARITY-Gastric01 global Phase III trial showed AstraZeneca’s (AZN) sonesitatug vedotin demonstrated a statistically significant and highly clinically meaningful improvement ...
AstraZeneca announces results from the SAFFRON Phase III trial of Tagrisso
AstraZeneca (AZN) announces positive results from the SAFFRON Phase III trial showed Tagrisso plus savolitinib demonstrated a statistically significant and clinically meaningful improvement in both pr...
AstraZeneca announces results from DeLLphi-305 trial of IMFINZI
Results from the DeLLphi-305 Phase III trial showed IMFINZI plus Amgen’s tarlatamab-dlle demonstrated a statistically significant and highly clinically meaningful improvement in the primary endpoint o...
AstraZeneca announces results from VOLGA Phase III trial of IMFINZI
Positive results from the VOLGA Phase III trial showed perioperative treatment with AstraZeneca’s (AZN) IMFINZI in combination with neoadjuvant enfortumab vedotin, EV, demonstrated statistically signi...
AstraZeneca's stomach cancer drug clears bar for extending overall survival in late-stage study
AstraZeneca's experimental drug sone-ve helped patients with advanced stomach cancer who had received at least two prior treatments to live longer than analysts had expected, according to late-stage t...
TAGRISSO® (osimertinib) plus savolitinib reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO
WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the SAFFRON Phase III trial showed TAGRISSO® (osimertinib) plus savolitinib demonstrated a statistically significant and clinically meaningful ...
Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer
WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the VOLGA Phase III trial showed perioperative treatment with AstraZeneca's IMFINZI® (durvalumab) in combination with neoadjuvant enfortumab ve...
China-made cancer drug to go on sale in US after Americans travel to buy it
Global pharmaceutical firm AstraZeneca said on Thursday it would start selling a cancer drug after coming under criticism for failing to bring it to the US market faster, prompting some Americans to f...
AstraZeneca PLC Announces US FDA Accelerated Approval of Ultomiris for IgAN on 22 October 2026
AstraZeneca PLC announced that Alexion, AstraZeneca Rare Disease’s Ultomiris (ravulizumab) has been approved in the US to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) ...
AstraZeneca announces US availability of Zegfrovy
AstraZeneca (AZN) announced the US availability of Zegfrovy for the treatment of adults with locally advanced or metastatic non-small cell lung cancer, NSCLC, whose tumors have epidermal growth factor...
ZEGFROVY® (sunvozertinib) now available in the US for patients with previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced the US availability of ZEGFROVY® (sunvozertinib) for the treatment of adults with locally advanced or metastatic non-small cell lung canc...
ZEGFROVY (sunvozertinib) now available in the US for patients with previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations
AstraZeneca today announced the US availability of ZEGFROVY (sunvozertinib) for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have epiderm...
AstraZeneca's Ultomiris Gets FDA Accelerated Approval As First C5 Inhibitor For IgAN
(RTTNews) - The U.S. FDA on Wednesday approved AstraZeneca (AZN) subsidiary Alexion's Ultomiris to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease pro...
AstraZeneca's Ultomiris Receives Accelerated FDA Approval for Kidney Disease Treatment
AstraZeneca's Ultomiris Receives Accelerated FDA Approval for Kidney Disease Treatment
AstraZeneca's Alexion Unit Gains FDA Nod for Ultomiris in IgAN, Ticker AZN
AstraZeneca's Alexion Unit Gains FDA Nod for Ultomiris in IgAN, Ticker AZN
AstraZeneca says FDA approves drug for rare kidney disease in adults
AstraZeneca says FDA approves drug for rare kidney disease in adults
AstraZeneca says Ultomiris approved to reduce proteinuria
The company states: “Alexion, AstraZeneca (AZN) Rare Disease’s Ultomiris – ravulizumab – has been approved in the US to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at...
Amgen (AMGN) and AstraZeneca Report Positive Phase 3 Trial Results for Tezspire in Eosinophilic ...
Amgen (AMGN) and AstraZeneca Report Positive Phase 3 Trial Results for Tezspire in Eosinophilic Esophagitis
AstraZeneca Stocks Rise 2.7% as Tezspire Data Sharpen Expansion Case
AstraZeneca Stocks Rise 2.7% as Tezspire Data Sharpen Expansion Case
AstraZeneca (AZN) Reports Positive Phase 3 CROSSING Trial Results for Eosinophilic Esophagitis ...
AstraZeneca (AZN) Reports Positive Phase 3 CROSSING Trial Results for Eosinophilic Esophagitis Treatment
AstraZeneca's Tezspire Shows Sustained Benefits In Phase 3 Esophagitis Trial
(RTTNews) - AstraZeneca (AZN) said Tuesday that full results from the Phase 3 CROSSING trial showed Tezspire improved disease remission and swallowing symptoms in adolescents and adults with eosinophi...
AstraZeneca reports full results from Phase 3 CROSSING trial of Tezspire
Full results from the “positive” Phase 3 CROSSING trial showed that AstraZeneca (AZN) and Amgen’s (AMGN) Tezspire demonstrated statistically significant and clinically meaningful improvements in the c...
AstraZeneca, Amgen announce TEZSPIRE showed ‘significant’ improvements
Full results from the Phase III CROSSING trial showed that AstraZeneca (AZN) and Amgen’s (AMGN) TEZSPIRE demonstrated statistically significant and clinically meaningful improvements in the co-primary...
AstraZeneca-Amgen asthma drug hits 69% remission in esophageal disease trial
AstraZeneca-Amgen asthma drug hits 69% remission in esophageal disease trial